Details:
Avenanthramides provide relief from a host of skin conditions, such as eczema, allergic rash, chicken pox and insect bites. Ceapro is the only commercial manufacturer of commercially available avenanthramides extracted and purified from oats.
Lead Product(s): Avenanthramide
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 22, 2022
Details:
AUR200 is a recombinant Fc fusion protein designed to specifically BAFF and APRIL. BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions.
Lead Product(s): AUR200
Therapeutic Area: Immunology Product Name: AUR200
Highest Development Status: IND Enabling Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 20, 2022
Details:
FSD Pharma holds exclusive worldwide (excluding Italy and Spain) licensing rights to FSD-201 for all conditions in all regulatory categories. FSD-201 (Palmitoylethanolamide) is a proprietary formulation of ultra-micronized palmitoylethanolamide (PEA).
Lead Product(s): Palmitoylethanolamide
Therapeutic Area: Immunology Product Name: FSD-201
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 31, 2022
Details:
BMND06, (a novel formulation based on the psychedelic molecule mescaline), is naturally occurring psychedelic compound, binding and activating, the serotonin 5-HT2A receptor with high affinity, for treating a wide range of therapeutic indications.
Lead Product(s): Mescaline
Therapeutic Area: Immunology Product Name: BMND06
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Tetra Bio-Pharma have initiated other research projects with Targeted Pharmaceuticals through its research agreement with the George Mason University NCBID to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications.
Lead Product(s): ARDS-003
Therapeutic Area: Immunology Product Name: ARDS-003
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Targeted Pharmaceuticals
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 26, 2021
Details:
Revive is currently in the process of preparing its Investigational New Drug (“IND”) application for submission to the U.S. Food and Drug Administration (“FDA”) for CBD in the treatment of AIH.
Lead Product(s): Cannabidiol
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2020